Turning FDA's 'Clunky' Drug Database Into A Useable Goldmine
The FDA's drug database, Drugs@FDA, is a goldmine of information. Unfortunately, because of the agency's "clunky" website, the data are difficult to access, search and aggregate, so the information's value is largely lost. But a group of scientists are using an $80,000 Open Science Prize to try to change that aggravating situation.
You may also be interested in...
Cancer therapies dominated US drug approvals in 2015, with the FDA's Center for Drug Evaluation and Research (CDER) also giving its nod to a record number of medicines that had gained orphan drug designation.
The FDA's Center for Drug Evaluation and Research (CDER) in 2014 had its best year in drug approvals since 1996 – clearing 41 new molecular entities (NMEs) and novel biologics over the past 12 months.
While the FDA's Center for Drug Evaluation and Research (CDER) approved 12 fewer new molecular entities (NMEs) and new therapeutic biologics in 2013 than it did in 2012 – 27 versus 39, respectively – the past year served as a springboard for the agency's new breakthrough therapy designation, with three medicines with the new status among the products gaining the agency's blessing to enter the US market.